Cochrane Evidence Synthesis and Methods ►

Neoadjuvant chemotherapy or chemoradiotherapy versus upfront surgery alone for resectable or borderline resectable pancreatic cancer

This is a protocol for a Cochrane Review (intervention). The objectives are as follows:

To compare the efficacy and safety of neoadjuvant chemotherapy or chemoradiotherapy versus upfront surgery alone in patients with resectable or borderline resectable pancreatic cancer.

This is a protocol.

Published:

27 October 2021

Authors:

Li J, Li X, Bai C, Yang K

See the full Review on

the Cochrane Library

►

Was this helpful? Donate.

If you found this evidence helpful, please consider donating to Cochrane. We are a charity that produces accessible evidence to help people make health and care decisions.
Donate
Print
PDF
Citation
Li J, Li X, Bai C, Yang K. Neoadjuvant chemotherapy or chemoradiotherapy versus upfront surgery alone for resectable or borderline resectable pancreatic cancer (Protocol). Cochrane Database of Systematic Reviews 2021, Issue 10. Art. No.: CD014618. DOI: 10.1002/14651858.CD014618.